
Please try another search
Wedbush analyst Liana Moussatos maintained a Buy rating on Intercept Pharma (NASDAQ:ICPT) on Friday, setting a price target of $140, which is approximately 281.26% above the present share price of $36.72.
Moussatos expects Intercept Pharma to post earnings per share (EPS) of -$1.92 for the fourth quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Intercept Pharma, with an average price target of $76.82.
The analysts price targets range from a high of $140 to a low of $48.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $77.25 million and a net profit of -$52.03 million. The company's market cap is $1.21 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.9% and a 47.54% success rate.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.